Windtree Therapeutics announced positive topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients with early cardiogenic shock. The study demonstrated significant improvement in systolic blood pressure and other key parameters, highlighting istaroxime’s potential as a treatment for this critical condition.
Windtree Therapeutics, Inc. (WINT) is seeing its stock rise after completing enrollment in its SEISMiC Extension Phase 2b study of istaroxime for early cardiogenic shock. This study builds upon positive results from a previous trial, focusing on longer dosing duration and exploring potential benefits of a tapering dosage regimen.
